238 reports of this reaction
1.8% of all CLADRIBINE reports
#12 most reported adverse reaction
MULTIPLE SCLEROSIS is the #12 most commonly reported adverse reaction for CLADRIBINE, manufactured by EMD Serono, Inc.. There are 238 FDA adverse event reports linking CLADRIBINE to MULTIPLE SCLEROSIS. This represents approximately 1.8% of all 13,464 adverse event reports for this drug.
Patients taking CLADRIBINE who experience multiple sclerosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS is a less commonly reported adverse event for CLADRIBINE, but still significant enough to appear in the safety profile.
In addition to multiple sclerosis, the following adverse reactions have been reported for CLADRIBINE:
The following drugs have also been linked to multiple sclerosis in FDA adverse event reports:
MULTIPLE SCLEROSIS has been reported as an adverse event in 238 FDA reports for CLADRIBINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS accounts for approximately 1.8% of all adverse event reports for CLADRIBINE, making it a notable side effect.
If you experience multiple sclerosis while taking CLADRIBINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.